Evaluation of the KRAS mutations in colorectal and pancreatic cancer patients
Main Article Content
Authors
D. Samatkyzy
Laboratory of genomic and personalized medicine, Private Institution National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan
S. Rakhimova
Laboratory of genomic and personalized medicine, Private Institution National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan
D. Begimbetova
Laboratory of translational medicine and Life Sciences Technologies, Private Institution National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan
A. Kukanova
NJSC “Astana Medical University”, Astana, Kazakhstan
F. Fazyl
Laboratory of translational medicine and Life Sciences Technologies, Private Institution National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan
I. Stefanov
“Multidisciplinary Medical Center”, Astana, Kazakhstan
O. Pirozhenko
“Multidisciplinary Medical Center”, Astana, Kazakhstan
A. Gabdulkayum
Laboratory of genomic and personalized medicine, Private Institution National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan
U. Kozhamkulov
Laboratory of genomic and personalized medicine, Private Institution National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan
A. Makishev
NJSC “Astana Medical University”, Astana, Kazakhstan
M. Tuleutayev
“Multidisciplinary Medical Center”, Astana, Kazakhstan
A. Akilzhanova
Laboratory of genomic and personalized medicine, Private Institution National Laboratory Astana, Nazarbayev University, Astana, Kazakhstan
D. Sarbassov
School of Sciences and Humanities, Nazarbayev University, Astana, Kazakhstan
Abstract
The RAS gene family is among the most studied and best characterized of the known cancer related genes. Of the three human RAS isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%–25% of all cancers. KRAS mutations are one of the most dominant mutations at 7% to 80% for colorectal cancer, 25% to 87% for pancreatic cancer, and 25% to 48% for lung cancer. The impact of KRAS mutations on the prognosis and survival of patients with adenocarcinoma and other types of cancer stimulates a lot of scientific research on their developmental mechanisms. To further develop a protocol for the treatment of mutant KRAS cases in Kazkahstan we study KRAS mutations status in Kazakhstani colorectal cancer and pancreatic patients. In this article, we review the literature on the role of KRAS mutation testing for management of patients and demonstrate preliminary data on KRAS mutation status in Kasakhstani patients with colorectal and pancreatic cancer.
Keywords
adenocarcinoma, RAS, KRAS, Sanger sequencing, missense mutation, codon
Article Details
References
Stratton, M. R., Campbell, P. J., & Futreal, P. A. (2009). The cancer genome // Nature. – vol.458, no. 7239. – p. 719–24. Crossref
Garraway, L. A., & Lander, E. S. (2013). Lessons from the cancer genome // Cell. – vol. 153, no.1, - p. 17–37. Crossref PMID: 23540688.
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., Jr, & Kinzler, K. W. (2013). Cancer genome landscapes // Science (New York, N.Y.), – vol. 339, no.6127, - p. 1546–1558. Crossref PMCID: PMC3749880.
Fearon, E. R., & Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis // Cell. – vol.61, no. 5. – p. 759–767. Crossref PMID: 2188735.
Watson, A. J., & Collins, P. D. (2011). Colon cancer: a civilization disorder // Digestive diseases (Basel, Switzerland). – vol.29, no.2. – p. 222-228. Crossref PMID: 21734388.
Rivera, B., González, S., Sánchez-Tomé, E., Blanco, I., Mercadillo, F., Letón, R., Benítez, J., Robledo, M., Capellá, G., & Urioste, M. (2011). Clinical and genetic characterization of classical forms of familial adenomatous polyposis: a Spanish population study // Annals of oncology : official journal of the European Society for Medical Oncology. – vol.22, no. 4. – p. 903–909. Crossref PMID: 20924072.
Manne, U., Shanmugam, C., Katkoori, V. R., Bumpers, H. L., & Grizzle, W. E. (2010). Development and progression of colorectal neoplasia // Cancer biomarkers : section A of Disease markers – vol. 9, no. 1-6. – p. 235–265. Crossref PMCID: PMC3445039.
Kastrinos, F., & Syngal, S. (2011). Inherited colorectal cancer syndromes // Cancer journal (Sudbury, Mass.). – vol. 17, no. 6. – p. 405–415. Crossref PMCID: PMC3240819.
Binefa, G., Rodríguez-Moranta, F., Teule, A., & Medina-Hayas, M. (2014). Colorectal cancer: from prevention to personalized medicine // World journal of gastroenterology. – vol. 20, no. 22. – p. 6786–6808. Crossref PMCID: PMC4051918.
Rojas, A. M., Fuentes, G., Rausell, A., & Valencia, A. (2012). The Ras protein superfamily: evolutionary tree and role of conserved amino acids // The Journal of cell biology. – vol. 196, no. 2. – p. 189–201. Crossref PMCID: PMC3265948.
Chang, E. H., Gonda, M. A., Ellis, R. W., Scolnick, E. M., & Lowy, D. R. (1982). Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses // Proceedings of the National Academy of Sciences of the United States of America. – vol. 79, no. 16. – p. 4848–4852. Crossref PMCID: PMC346782.
Kranenburg O. (2005). The KRAS oncogene: past, present, and future // Biochimica et biophysica acta. – vol. 1756, no. 2. – p. 81–82. Crossref PMID: 16269215.
Almoguera, C., Shibata, D., Forrester, K., Martin, J., Arnheim, N., & Perucho, M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes // Cell. – vol. 53, no. 4. – p. 549–554. Crossref PMID: 2453289.
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J. L., Peeters, M., Humblet, Y., Van Cutsem, E., & Tejpar, S. (2008). KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab // Annals of oncology : official journal of the European Society for Medical Oncology. – vol. 19, no. 3. – p. 508–515. Crossref PMID: 17998284.
Bell, S. M., Scott, N., Cross, D., Sagar, P., Lewis, F. A., Blair, G. E., Taylor, G. R., Dixon, M. F., & Quirke, P. (1993). Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer // Gastroenterology. – vol. 104, no. 1. – p. 57–64. Crossref PMID: 8419262.
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M., & Bos, J. L. (1988). Genetic alterations during colorectal-tumor development // The New England journal of medicine. – vol. 319, no. 9. – p. 525–532. Crossref PMID: 2841597.
Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., Flanagan, A., Teague, J., Futreal, P. A., Stratton, M. R., & Wooster, R. (2004). The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website // British journal of cancer. – vol. 91, no. 2. – p. 355–358. Crossref PMCID: PMC2409828.
Rodenhuis, S., Slebos, R. J., Boot, A. J., Evers, S. G., Mooi, W. J., Wagenaar, S. S., van Bodegom, P. C., & Bos, J. L. (1988). Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung // Cancer research. – vol. 48, no. 20. – p. 5738–5741. PMID: 3048648.
Yoshizawa, R., Umeki, N., Yanagawa, M., Murata, M., & Sako, Y. (2017). Single-molecule fluorescence imaging of RalGDS on cell surfaces during signal transduction from Ras to Ral. Biophysics and physicobiology, – vol. 14. – p. 75–84. Crossref PMCID: PMC5515350.
Kolch W. (2000). Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions // The Biochemical journal. – vol. 351 Pt 2, no. Pt 2. – p. 289–305. PMCID: PMC1221363.
Castellano, E., Sheridan, C., Thin, M. Z., Nye, E., Spencer-Dene, B., Diefenbacher, M. E., Moore, C., Kumar, M. S., Murillo, M. M., Grönroos, E., Lassailly, F., Stamp, G., & Downward, J. (2013). Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance // Cancer cell. – vol. 24, no. 5. – p. 617–630. Crossref PMCID: PMC3826036.
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011). RAS oncogenes: weaving a tumorigenic web // Nature reviews. Cancer. – vol. 11, no. 11. – p. 761–774. Crossref PMCID: PMC3632399.
Zhu, G., Pei, L., Xia, H., Tang, Q., & Bi, F. (2021). Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer // Molecular cancer. – vol. 20, no. 1. – p. 143. Crossref PMCID: PMC8571891
Shingu, T., Holmes, L., Henry, V., Wang, Q., Latha, K., Gururaj, A. E., Gibson, L. A., Doucette, T., Lang, F. F., Rao, G., Yuan, L., Sulman, E. P., Farrell, N. P., Priebe, W., Hess, K. R., Wang, Y. A., Hu, J., & Bögler, O. (2016). Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells // Journal of translational medicine. – vol. 14. – p. 46. Crossref PMCID: PMC4746796.
Van Schaeybroeck, S., Kalimutho, M., Dunne, P. D., Carson, R., Allen, W., Jithesh, P. V., Redmond, K. L., Sasazuki, T., Shirasawa, S., Blayney, J., Michieli, P., Fenning, C., Lenz, H. J., Lawler, M., Longley, D. B., & Johnston, P. G. (2014). ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer // Cell reports. – vol. 7, no. 6. – p. 1940–1955. Crossref PMID: 24931611.
Chu, P. C., Lin, P. C., Wu, H. Y., Lin, K. T., Wu, C., Bekaii-Saab, T., Lin, Y. J., Lee, C. T., Lee, J. C., & Chen, C. S. (2018). Mutant KRAS promotes liver metastasis of colorectal cancer, in part, by upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR signaling pathway // Oncogene. – vol. 37, no. 25. – p. 3440–3455. Crossref PMID: 29559746.
Cannon, A. C., Uribe-Alvarez, C., & Chernoff, J. (2020). RAC1 as a Therapeutic Target in Malignant Melanoma // Trends in cancer. – vol. 6, no. 6. – p. 478–488. Crossref PMCID: PMC7380552.
Tsunoda, T., Takashima, Y., Fujimoto, T., Koyanagi, M., Yoshida, Y., Doi, K., Tanaka, Y., Kuroki, M., Sasazuki, T., & Shirasawa, S. (2010). Three-dimensionally specific inhibition of DNA repair-related genes by activated KRAS in colon crypt model // Neoplasia (New York, N.Y.). – vol. 12, no. 5. – p. 397–404. Crossref PMCID: PMC2864477.
Petanidis, S., Anestakis, D., Argyraki, M., Hadzopoulou-Cladaras, M., & Salifoglou, A. (2013). Differential expression of IL-17, 22 and 23 in the progression of colorectal cancer in patients with K-ras mutation: Ras signal inhibition and crosstalk with GM-CSF and IFN-γ // PloS one. – vol. 8, no. 9. – p. e73616. Crossref PMCID: PMC3765247.
Davidson, C. J., Zeringer, E., Champion, K. J., Gauthier, M. P., Wang, F., Boonyaratanakornkit, J., Jones, J. R., & Schreiber, E. (2012). Improving the limit of detection for Sanger sequencing: a comparison of methodologies for KRAS variant detection // BioTechniques. – vol. 53, no. 3. – p. 182–188. Crossref PMID: 22963480.
Development of an Interlaboratory-Verified Sequencing Workflow for KRAS Variant Identification // Application note KRAS Variant Identification, Applied Biosystems.
Bukovac, A., Kafka, A., Hrašćan, R., Vladušić, T., & Pećina-Šlaus, N. (2019). Nucleotide variations of TP53 exon 4 found in intracranial meningioma and in silico prediction of their significance // Molecular and clinical oncology. – vol. 11, no. 6. – p. 563–572. Crossref PMCID: PMC6826266.
Jiang, W., Xiang, L., Pei, X., He, T., Shen, X., Wu, X., & Yang, H. (2018). Mutational analysis of KRAS and its clinical implications in cervical cancer patients // Journal of gynecologic oncology. – vol. 29, no. 1. – p. e4. Crossref PMCID: PMC5709530.
Angeles, A., Yu, R., Cutiongco-De La Paz, E. M., & Garcia, R. L. (2019). Phenotypic characterization of the novel, non-hotspot oncogenic KRAS mutants E31D and E63K // Oncology letters. – vol. 18, no. 1. – p. 420–432. Crossref PMCID: PMC6540134.
Kavec, M. J., Urbanova, M., Makovicky, P., Opattová, A., Tomasova, K., Kroupa, M., Kostovcikova, K., Siskova, A., Navvabi, N., Schneiderova, M., Vymetalkova, V., Vodickova, L., & Vodicka, P. (2022). Oxidative Damage in Sporadic Colorectal Cancer: Molecular Mapping of Base Excision Repair Glycosylases MUTYH and hOGG1 in Colorectal Cancer Patients // International journal of molecular sciences. – vol. 23, no. 10. – p. 5704. Crossref PMCID: PMC9145200.
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., Hong, S. M., Fu, B., Lin, M. T., Calhoun, E. S., Kamiyama, M., Walter, K., Nikolskaya, T., Nikolsky, Y., Hartigan, J., Smith, D. R., … Kinzler, K. W. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses // Science (New York, N.Y.). – vol. 321, no. 5897. – p. 1801–1806. Crossref PMCID: PMC2848990.
Wang, Q., Mehmood, A., Wang, H., Xu, Q., Xiong, Y., & Wei, D. Q. (2019). Computational Screening and Analysis of Lung Cancer Related Non-Synonymous Single Nucleotide Polymorphisms on the Human Kirsten Rat Sarcoma Gene // Molecules (Basel, Switzerland). – vol. 24, no. 10. – p. 1951. Crossref PMCID: PMC6572712.
Feng, S., Callow, M. G., Fortin, J. P., Khan, Z., Bray, D., Costa, M., Shi, Z., Wang, W., & Evangelista, M. (2022). A saturation mutagenesis screen uncovers resistant and sensitizing secondary KRAS mutations to clinical KRASG12C inhibitors // Proceedings of the National Academy of Sciences of the United States of America. – vol. 119, no. 18. – p. e2120512119. Crossref PMCID: PMC9170150.
Jauhri, M., Bhatnagar, A., Gupta, S., Bp, M., Minhas, S., Shokeen, Y., & Aggarwal, S. (2017). Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study // Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. – vol. 39, no. 2. – p. 1010428317692265. Crossref PMID: 28222664.
Luo J. (2021). KRAS mutation in pancreatic cancer // Seminars in oncology. – vol. 48, no. 1. – p. 10–18. Crossref PMCID: PMC8380752.
Adapted from URL
García-Alfonso, P., Grande, E., Polo, E., Afonso, R., Reina, J. J., Jorge, M., Campos, J. M., Martínez, V., Angeles, C., & Montagut, C. (2014). The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status. Angiogenesis. – vol. 17, no. 4. – p. 805–821. Crossref PMID: 24793846.